A Harvard neuroscientist is warning a federal court that moving marijuana to a lower schedule under federal law could have unintended consequences, especially when it comes to research, regulation, and how the drug is viewed in medicine and public policy.
The expert argues that while rescheduling cannabis is often seen as a step toward reform, it could also create confusion in the scientific and medical communities if the change is not backed by clear evidence standards and consistent federal guidelines.
The court filing comes as federal agencies continue to debate how marijuana should be classified under the Controlled Substances Act, a decision that affects everything from research access to criminal penalties and medical use rules.
Supporters of rescheduling say it would recognize the plant’s medical potential and reduce unnecessary restrictions on research. Critics, including some scientists, caution that moving too quickly could lead to gaps in regulation and unclear messaging about risks and benefits.
The debate highlights a growing divide between policy reform efforts and concerns from parts of the scientific community about how changes are being implemented.
At the center of the issue is a bigger question: how to balance expanding access and research with maintaining clear, evidence-based public health standards.
Dabbin-Dad Newsroom
